Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University of Texas Southwestern Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07446257CT.gov THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07543783CT.gov Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial | — | Not Yet Recruiting | — | — | — |
NCT06893887CT.gov Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06789848CT.gov Ligufalimab and Cadonilimab in Advanced Liver Cancers | — | Recruiting | — | — | — |
NCT06618664CT.gov A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06530251CT.gov A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Recruiting | — | — | — |
NCT06406634CT.gov Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06405061CT.gov Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma | — | Suspended | — | — | — |
NCT06261125CT.gov Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) | — | Recruiting | — | — | — |
NCT06265350CT.gov Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases | — | Recruiting | — | — | — |
Show 24 more trialsShow fewer
NCT06187961CT.gov HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05975463CT.gov Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy | — | Not Yet Recruiting | — | — | — |
NCT06040177CT.gov Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | — | Unknown | — | — | — |
NCT05578430CT.gov AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | — | Unknown | — | — | — |
NCT05882370CT.gov TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | — | Recruiting | — | — | — |
NCT05261399CT.gov Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | — | Active Not Recruiting | — | — | — |
NCT05444088CT.gov Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05472896CT.gov TACE With Dicycloplatin(TP21) in Unresectable HCC | — | Unknown | — | — | — |
NCT05241873CT.gov (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | — | Terminated | — | — | — |
NCT05153408CT.gov (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04807166CT.gov Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04653389CT.gov Perioperative Therapy for Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04175912CT.gov Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | — | Active Not Recruiting | — | — | — |
NCT03952403CT.gov A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT03533582CT.gov Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | — | Active Not Recruiting | — | — | — |
NCT03017326CT.gov Paediatric Hepatic International Tumour Trial | — | Active Not Recruiting | — | — | — |
NCT01755767CT.gov Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | — | Completed | — | — | — |
NCT01375569CT.gov TRC105 for Liver Cancer That Has Not Responded to Sorafenib | — | Completed | — | — | — |
NCT01253681CT.gov Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | — | Completed | — | — | — |
NCT01016054CT.gov A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | — | Terminated | — | — | — |
NCT00599755CT.gov Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3) | — | Completed | — | — | — |
NCT00152477CT.gov A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | University of Texas Southwestern Medical Center | Approved | BB · 66 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-hepatocellular-carcinoma-109165
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →